Abstract

Objective: Diabetic nephropathy is one of the most common causes of end-stage renal failure. Inhibition of ACE2 function accelerates diabetic kidney injury while renal ACE2 is downregulated in diabetic nephropathy. We examined the ability of human recombinant ACE2 (hrACE2) to slow the progression of diabetic kidney injury.

Research Design and Methods: Male 12-week old diabetic Akita mice (Ins2^WT/C96Y) and control C57BL/6J mice (Ins2^WT/WT) were injected daily with placebo or with rhACE2 (2 mg/kg, i.p.) for four weeks. Albumin excretion, gene expression, histomorphometry, NADPH oxidase activity and peptide levels were examined. The effect of hrACE2 on high glucose and Ang II-induced changes was also examined in cultured mesangial cells.

Results: Treatment with hrACE2 increased plasma ACE2 activity, normalized blood pressure, and reduced the urinary albumin excretion in Akita Ins2^WT/C96Y mice in association with a decreased glomerular mesangial matrix expansion and normalization of increased alpha-SMA and collagen III expression. Human recombinant ACE2 increased Ang 1-7 levels, lowered Ang II levels and reduced NADPH oxidase activity. mRNA levels for p47^phox and NOX2 and protein levels for PKCα and PKCβ1 were also normalized by treatment with hrACE2. In vitro, hrACE2 attenuated both high glucose and ANG II-induced oxidative stress and NADPH oxidase activity.

Conclusions: Treatment with hrACE2 attenuates diabetic kidney injury in the Akita mouse in association with a reduction in blood pressure and a decrease in NADPH oxidase activity. In vitro studies show that the protective effect of hrACE2 is due to reduction in Ang II and an increase in Ang 1-7 levels.